secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-058981
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production
--------------------------------------------------------------------------------

- Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.
- Elevated Softgels is a GMP-certified, FDA-registered manufacturer of softgels and tinctures.
- CEO says acquisition expected to be accretive in first year; softgels and tinctures were ~50% of 2023 sales.
- Plans to in-source manufacturing of +PlusCBD branded products for meaningful cost savings.
- Earnout thresholds: $200k if net revenue ≥$700k in 12 months, $0 if <$550k, with intermediate steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000095017024058981/0000950170-24-058981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000095017024058981/cvsi-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer